Clinical Trials Browser

INDUSTRY × Thyroid Neoplasms × cabozantinib × Clear all

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase 3 Active not recruiting

187 enrolled 13 charts 1 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01896479 2025-09-02

EXAMINER

Phase 4 Active not recruiting

247 enrolled 14 charts

Thyroid Neoplasms, Carcinoma, Medullary